Lumos Pharma Inc

Company Profile

Lumos Pharma Inc had its IPO on 2011-11-11 under the ticker symbol LUMO.

The company operates in the Healthcare sector and Biotechnology industry. Lumos Pharma Inc has a staff strength of 32 employees.

Stock update

Shares of Lumos Pharma Inc opened at $3.3 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $3.26 - $3.35, and closed at $3.26.

This is a 0% increase from the previous day's closing price.

A total volume of 3,524 shares were traded at the close of the day’s session.

In the last one week, shares of Lumos Pharma Inc have increased by +8.31%.

Lumos Pharma Inc's Key Ratios

Lumos Pharma Inc has a market cap of $23.89 million, indicating a price to book ratio of 0.4045 and a price to sales ratio of 22.4545.

In the last 12-months Lumos Pharma Inc’s revenue was $2.23 million with a gross profit of $1.52 million and an EBITDA of $-34006000. The EBITDA ratio measures Lumos Pharma Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Lumos Pharma Inc’s operating margin was -1529.55% while its return on assets stood at -30.02% with a return of equity of -53.76%.

In Q2, Lumos Pharma Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 30.8%.

Lumos Pharma Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-3.92 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Lumos Pharma Inc’s profitability.

Lumos Pharma Inc stock is trading at a EV to sales ratio of 1.1098 and a EV to EBITDA ratio of 1.5642. Its price to sales ratio in the trailing 12-months stood at 22.4545.

Lumos Pharma Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$56.37 million

Total Liabilities

$6.55 million

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

Lumos Pharma Inc ended 2024 with $56.37 million in total assets and $0 in total liabilities. Its intangible assets were valued at $56.37 million while shareholder equity stood at $43.66 million.

Lumos Pharma Inc ended 2024 with $0 in deferred long-term liabilities, $6.55 million in other current liabilities, 80000.00 in common stock, $-143760000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $37.86 million and cash and short-term investments were $50.85 million. The company’s total short-term debt was $179,000 while long-term debt stood at $0.

Lumos Pharma Inc’s total current assets stands at $55.98 million while long-term investments were $0 and short-term investments were $12.99 million. Its net receivables were $233000.00 compared to accounts payable of $279000.00 and inventory worth $0.

In 2024, Lumos Pharma Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Lumos Pharma Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$3.26

52-Week High

$9.56

52-Week Low

$2.63

Analyst Target Price

$17.5

Lumos Pharma Inc stock is currently trading at $3.26 per share. It touched a 52-week high of $9.56 and a 52-week low of $9.56. Analysts tracking the stock have a 12-month average target price of $17.5.

Its 50-day moving average was $3.13 and 200-day moving average was $3.49 The short ratio stood at 10.44 indicating a short percent outstanding of 0%.

Around 3415.9% of the company’s stock are held by insiders while 2750.8% are held by institutions.